Vaccine Breakthrough Infections with SARS-CoV-2 Variants

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

Rambaut, A., Holmes, E. C., O’Toole, Á., Hill, V., McCrone, J. T., Ruis, C., du Plessis, L., & Pybus, O. G. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0770-5 · Cited by 2,543

Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals

Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853

Evolution of antibody immunity to SARS-CoV-2

Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020) · eLife · doi:10.7554/elife.61312 · Cited by 1,308

SARS-CoV-2 evolution during treatment of chronic infection

Kemp, S. A., Collier, D. A., Datir, R. P., Ferreira, I. A. T. M., Gayed, S., Jahun, A., Hosmillo, M., Rees-Spear, C., Mlcochova, P., Lumb, I. U., et al. (2021) · Nature · doi:10.1038/s41586-021-03291-y · Cited by 1,097

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Planas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C., Buchrieser, J., Rajah, M. M., Bishop, E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01318-5 · Cited by 697

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric virusesPreprint

Schmidt, F., Weisblum, Y., Muecksch, F., Hoffmann, H., Michailidis, E., Lorenzi, J. C. C., Mendoza, P., Rutkowska, M., Bednarski, E., Gaebler, C., et al. (2020) · bioRxiv · doi:10.1101/2020.06.08.140871 · Cited by 600

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

Schmidt, F., Weisblum, Y., Muecksch, F., Hoffmann, H.-H., Michailidis, E., Lorenzi, J. C. C., Mendoza, P., Rutkowska, M., Bednarski, E., Gaebler, C., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20201181 · Cited by 572

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Stamatatos, L., Czartoski, J., Wan, Y.-H., Homad, L. J., Rubin, V., Glantz, H., Neradilek, M., Seydoux, E., Jennewein, M. F., MacCamy, A. J., et al. (2021) · Science · doi:10.1126/science.abg9175 · Cited by 557

Effect of COVID-19 vaccination on the SARS-CoV-2 transmission among social and household close contacts: A cohort study

Martínez‐Baz, I., Miqueleiz, A., Egüés, N., Casado, I., Burgui, C., Echeverría, A., Navascués, A., Fernández-Huerta, M., Cenoz, M. G., Trobajo‐Sanmartín, C., et al. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.01.017 · Cited by 26

SARS-CoV-2 Delta Variant Breakthrough Infection and Onward Secondary Transmission in Household

Yi, S., Kim, J.-M., Choe, Y. J., Hong, S., Choi, S., Ahn, S. B., Kim, M., & Park, Y.-J. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2022.37.e12 · Cited by 22

Robust Antibody Responses to the BNT162b2 mRNA Vaccine Occur Within a Week After the First Dose in Previously Infected Individuals and After the Second Dose in Uninfected Individuals

Hirotsu, Y., Amemiya, K., Sugiura, H., Shinohara, M., Takatori, M., Mochizuki, H., & Omata, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.722766 · Cited by 22

Results of the RENAISSANCE Study: REsponse to BNT162b2 COVID-19 vacciNe—short- And long-term Immune reSponSe evAluatioN in health Care workErs

Pani, A., Cento, V., Vismara, C., Campisi, D., Ruscio, F. D., Romandini, A., Senatore, M., Schenardi, P. A., Gagliardi, O. M., Giroldi, S., et al. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.08.013 · Cited by 22

Symptomatic post-vaccination SARS-CoV-2 infections in healthcare workers– A multicenter cohort study

Vaishya, R., Sibal, A., Malani, A., Kar, S., Hari Prasad, K., Kiran, S. V., Reddy, S., Kamineni, S., Reddy, S., Reddy, P. A., et al. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.102306 · Cited by 22

SARS-CoV-2 mRNA Vaccine Breakthrough Infections in Fully Vaccinated Healthcare Personnel: A Systematic Review

Ledda, C., Costantino, C., Motta, G., Cunsolo, R., Stracquadanio, P., Liberti, G., Maltezou, H. C., & Rapisarda, V. (2022) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed7010009 · Cited by 22

Pharmacologic Ascorbic Acid as Early Therapy for Hospitalized Patients with COVID-19: A Randomized Clinical Trial

Coppock, D., Violet, P.-C., Vásquez, G., Belden, K. A., Foster, M. W., Mullin, B., Magee, D., Mikell, I., Shah, L., Powers, V., et al. (2022) · Life · doi:10.3390/life12030453 · Cited by 21

Enhanced neutrophil extracellular trap formation in COVID-19 is inhibited by the protein kinase C inhibitor ruboxistaurin

Dowey, R., Cole, J., Thompson, A. A. R., Huang, C., Whatmore, J., Iqbal, A., Bradley, K. L., Mckenzie, J., Hull, R. C., Lawrie, A., et al. (2022) · ERJ Open Research · doi:10.1183/23120541.00596-2021 · Cited by 22

SARS-CoV-2 Point Mutation and Deletion Spectra and Their Association with Different Disease Outcomes

Martínez‐González, B., Soria, M. E., Vázquez-Sirvent, L., Ferrer‐Orta, C., Lobo-Vega, R., Mínguez, P., de la Fuente, L., Lloréns, C., Soriano, B., Ramos, R., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00221-22 · Cited by 22

A fast extraction-free isothermal LAMP assay for detection of SARS-CoV-2 with potential use in resource-limited settings

Gärtner, K., Meleke, H., Kamdolozi, M., Chaima, D., Samikwa, L., Paynter, M., Nyirenda-Nyang’wa, M., Cloutman-Green, E., Nastouli, E., Klein, N. J., et al. (2022) · Virology Journal · doi:10.1186/s12985-022-01800-7 · Cited by 22

Modeling the kinetics of the neutralizing antibody response against SARS-CoV-2 variants after several administrations of Bnt162b2

Clairon, Q., Prague, M., Planas, D., Bruel, T., Hocqueloux, L., Prazuck, T., Schwartz, O., Thiébaut, R., & Guedj, J. (2023) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011282 · Cited by 25

Antigenic minimalism of SARS-CoV-2 is linked to surges in COVID-19 community transmission and vaccine breakthrough infectionsPreprint

Venkatakrishnan, A., Anand, P., Lenehan, P. J., Ghosh, P., Suratekar, R., Siroha, A., Chowdhury, D. R., O’Horo, J. C., Yao, J. D. C., Pritt, B. S., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-555451/v1 · Cited by 22

Advances in the study of LNPs for mRNA delivery and clinical applications

Wang, B., Shen, B., Xiang, W., & Shen, H. (2024) · Virus Genes · doi:10.1007/s11262-024-02102-6 · Cited by 22

What should define a SARS-CoV-2 “breakthrough” infection?

Schieffelin, J. S., Norton, E. B., & Kolls, J. K. (2021) · Journal of Clinical Investigation · doi:10.1172/jci151186 · Cited by 22

Breakthrough Infections with Multiple Lineages of SARS-CoV-2 Variants Reveals Continued Risk of Severe Disease in Immunosuppressed Patients

Deng, X., Evdokimova, M., O’Brien, A., Rowe, C. L., Clark, N. M., Harrington, A., Reid, G., Uprichard, S. L., & Baker, S. C. (2021) · Viruses · doi:10.3390/v13091743 · Cited by 21

Application of omics technology to combat the COVID‐19 pandemic

Yang, J., Yan, Y., & Zhong, W. (2021) · MedComm · doi:10.1002/mco2.90 · Cited by 20

Three doses of prototypic SARS-CoV-2 inactivated vaccine induce cross-protection against its variants of concern

Xie, T., Lu, S., He, Z., Liu, H., Wang, J., Tang, C., Yang, T., Yu, W., Li, H., Yang, Y., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00920-4 · Cited by 20

COVID-19 Vaccines against Omicron Variant: Real-World Data on Effectiveness

Kherabi, Y., Launay, O., & Nguyen, L. B. L. (2022) · Viruses · doi:10.3390/v14102086 · Cited by 20

Durability of Neutralization Against Omicron Subvariants after Vaccination and Breakthrough Infection

Zhu, K.-L., Jiang, X., Zhan, B., Wang, X., Xia, X., Cao, G.-P., Sun, W., Huang, P., Zhang, J., Gao, Y.-L., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2023.112075 · Cited by 20

Increased flexibility of the SARS-CoV-2 RNA-binding site causes resistance to remdesivir

Torii, S., Kim, K. S., Koseki, J., Suzuki, R., Iwanami, S., Fujita, Y., Jeong, Y. D., Ito, J., Asakura, H., Nagashima, M., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011231 · Cited by 23

The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillancePreprint

Tegally, H., San, J. E., Cotten, M. L., Tegomoh, B., Mboowa, G., Martin, D. P., Baxter, C., Moir, M., Lambisia, A. W., Diallo, A. B., et al. (2022) · medRxiv · doi:10.1101/2022.04.17.22273906 · Cited by 21

Post-Vaccination Coronavirus Disease 2019: A Case-Control Study and Genomic Analysis of 119 Breakthrough Infections in Partially Vaccinated Individuals

Baltas, I., Boshier, F. A. T., Williams, C. A., Bayzid, N., Cotic, M., Guerra‐Assunção, J. A., Irish, D. N., Haque, T., Hart, J., Roy, S., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab714 · Cited by 22

Genomic, immunological, and clinical analysis of COVID‐19 vaccine breakthrough infections in Beijing, China

Tian, D., Song, Y., Zhang, M., Pan, Y., Ge, Z., Zhang, Y., Ren, X., Wen, J., Xu, Y., Guo, H., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27636 · Cited by 18

Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients

Wand, O., Nacasch, N., Fadeela, A., Shashar, M., Grupper, A., Benchetrit, S., Erez, D., Shitrit, P., & Cohen‐Hagai, K. (2022) · Journal of Nephrology · doi:10.1007/s40620-022-01245-9 · Cited by 19

Global trends in COVID-19

Zhou, C., Qin, X., Yan, L., Jiang, Y., & Yu, X. (2022) · Infectious Medicine · doi:10.1016/j.imj.2021.08.001 · Cited by 21

Using Dual Toll-like Receptor Agonism to Drive Th1-Biased Response in a Squalene- and α-Tocopherol-Containing Emulsion for a More Effective SARS-CoV-2 Vaccine

Short, K. K., Lathrop, S. K., Davison, C. J., Partlow, H. A., Kaiser, J. A., Tee, R. D., Lorentz, E. B., Evans, J. T., & Burkhart, D. J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071455 · Cited by 21

Effectiveness of Booster Dose of Anti SARS-CoV-2 BNT162b2 in Cirrhosis: Longitudinal Evaluation of Humoral and Cellular Response

Giambra, V., Piazzolla, V., Cocomazzi, G., Squillante, M. M., Santis, E. D., Totti, B., Cavorsi, C., Giuliani, F., Serra, N., & Mangia, A. (2022) · Vaccines · doi:10.3390/vaccines10081281 · Cited by 20

A modeling-based approach to optimize COVID-19 vaccine dosing schedules for improved protection

Dogra, P., Schiavone, C., Wang, Z., Ruiz-Ramírez, J., Caserta, S., Staquicini, D. I., Markosian, C., Wang, J., Sostman, D. H., Pasqualini, R., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.169860 · Cited by 21

Reinfections in COVID-19 Patients: Impact of Virus Genetic Variability and Host Immunity

Fakhroo, A. D., Al-Khatib, H. A., Thani, A. A. A., & Yassine, H. M. (2021) · Vaccines · doi:10.3390/vaccines9101168 · Cited by 21

Geographical prevalence of SARS-CoV-2 variants, August 2020 to July 2021

Chan, W. S., Lam, Y. M., Law, J. H. Y., Chan, T. L., Ma, E. S. K., & Tang, B. S. F. (2022) · Scientific Reports · doi:10.1038/s41598-022-08684-1 · Cited by 20

Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants

Wang, X., Lin, Y., Zhang, H.-Y., Zhu, K.-L., Zhao, J., Zhan, B., Li, Y., He, X.-J., Huang, C., Wang, Z.-Y., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01151-6 · Cited by 18

SARS-CoV-2 Inactivation in Aerosol by Means of Radiated Microwaves

Manna, A., Forni, D. D., Bartocci, M., Pasculli, N., Poddesu, B., Lista, F. R., Santis, R. D., Amatore, D., Grilli, G., Molinari, F., et al. (2023) · Viruses · doi:10.3390/v15071443 · Cited by 19

Transmission dynamics informed neural network with application to COVID-19 infections

He, M., Tang, B., Xiao, Y., & Tang, S. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107431 · Cited by 18

SARS-CoV-2 viral titer measurements in Ontario, Canada wastewaters throughout the COVID-19 pandemic

D’Aoust, P. M., Hegazy, N., Ramsay, N. T., Yang, M. I., Dhiyebi, H. A., Edwards, E. A., Servos, M. R., Ybazeta, G., Habash, M., Goodridge, L. D., et al. (2024) · Scientific Data · doi:10.1038/s41597-024-03414-w · Cited by 19

Reopening International Borders without Quarantine: Contact Tracing Integrated Policy against COVID-19

Yu, Z., Zhu, X., Liu, X., Chen, X., Wei, T., Yuan, H.-Y., Xu, Y., Zhu, R., He, H., Wong, M. S., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18147494 · Cited by 18

Long-Lasting Immunity Against SARS-CoV-2: Dream or Reality?

Gussarow, D., Bonifacius, A., Cossmann, A., Stankov, M. V., Mausberg, P., Tischer‐Zimmermann, S., Gödecke, N., Kalinke, U., Behrens, G. M. N., Blasczyk, R., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.770381 · Cited by 18

Computational Design of Miniproteins as SARS-CoV-2 Therapeutic Inhibitors

Jawad, B., Adhikari, P., Cheng, K., Podgornik, R., & Ching, W. Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020838 · Cited by 16

Potent antibody immunity to SARS‐CoV‐2 variants elicited by a third dose of inactivated vaccine

Ju, B., Zhou, B., Song, S., Fan, Q., Ge, X., Wang, H., Cheng, L., Guo, H., Shu, D., Liu, L., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.732 · Cited by 17

Convergent Evolution of Multiple Mutations Improves the Viral Fitness of SARS-CoV-2 Variants by Balancing Positive and Negative Selection

Upadhyay, V., Patrick, C., Lucas, A., & Mallela, K. M. G. (2022) · Biochemistry · doi:10.1021/acs.biochem.2c00132 · Cited by 17

Breakthrough COVID-19 Infections in the US: Implications for Prolonging the Pandemic

Alcendor, D. J., Matthews-Juarez, P., Smoot, D. T., Hildreth, J. E. K., Lamar, K. D., Tabatabai, M., Wilus, D. M., & Juárez, P. D. (2022) · Vaccines · doi:10.3390/vaccines10050755 · Cited by 18

In vitro inhibition of SARS-CoV-2 Infection by dry algae powders

García-Ruíz, D., Villalobos-Sánchez, E., Alam-Escamilla, D., & Elizondo‐Quiroga, D. (2022) · Scientific Reports · doi:10.1038/s41598-022-22148-6 · Cited by 21

Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics

Pérez‐Vargas, J., Shapira, T., Olmstead, A. D., Villanueva, I., Thompson, C. A. H., Ennis, S., Gao, G., Guzman, J. D., Williams, D. E., Wang, M., et al. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105484 · Cited by 19

Functionalized Fullerene for Inhibition of SARS‐CoV‐2 Variants

Page, T. M., Nie, C., Neander, L., Povolotsky, T. L., Sahoo, A. K., Nickl, P., Adler, J. M., Bawadkji, O., Radnik, J., Achazi, K., et al. (2023) · Small · doi:10.1002/smll.202206154 · Cited by 19

Anti-SARS-CoV-2 Activity of Extracellular Vesicle Inhibitors: Screening, Validation, and Combination with Remdesivir

Kongsomros, S., Suksatu, A., Kanjanasirirat, P., Manopwisedjaroen, S., Prasongtanakij, S., Jearawuttanakul, K., Borwornpinyo, S., Hongeng, S., Thitithanyanont, A., & Chutipongtanate, S. (2021) · Biomedicines · doi:10.3390/biomedicines9091230 · Cited by 18

Large-Scale Structure-Based Screening of Potential T Cell Cross-Reactivities Involving Peptide-Targets From BCG Vaccine and SARS-CoV-2

Tarabini, R. F., Rigo, M., Fonseca, A. F., Rubin, F. P., Belle, R. L., Kavraki, L. E., Ferreto, T. C., Antunes, D. A., & de Souza, A. P. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.812176 · Cited by 16

Breakthrough SARS-CoV-2 infections after COVID-19 immunization

Hirsh, J., Htay, T., Bhalla, S., Nguyen, V. T., & Cervantes, J. (2022) · Journal of Investigative Medicine · doi:10.1136/jim-2021-002131 · Cited by 16

Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice

Horvath, D. J., Temperton, N. J., Neto, M. M., Costa, K. D., Cantoni, D. M., Horlacher, R., Günther, A., Brosig, A., Morath, J., Jakobs, B., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-31198-3 · Cited by 16

Emerging Landscape of Nanobodies and Their Neutralizing Applications against SARS-CoV-2 Virus

Feng, X., & Wang, H. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00042 · Cited by 19

Positivity rate: an indicator for the spread of COVID-19

Dallal, A. A., AlDallal, U., & Dallal, J. A. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1980868 · Cited by 18

COVID-19 Vaccine Breakthrough Infections in Veterans Health AdministrationPreprint

Sharma, A., Oda, G., & Holodniy, M. (2021) · medRxiv · doi:10.1101/2021.09.23.21263864 · Cited by 17

Lessons learned from the COVID-19 control strategy of the XXXII Tokyo Summer Olympics and the XXIV Beijing Winter Olympics

Zhang, Y., Ai, J., Bao, J., & Zhang, W. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2090859 · Cited by 17

Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera

Miyakawa, K., Jeremiah, S. S., Kato, H., Yamaoka, Y., Go, H., Yajima, S., Shimada, T., Mihara, T., Goto, A., Yamanaka, T., et al. (2021) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjab050 · Cited by 17

SARS-CoV-2 Reinfection Is a New Challenge for the Effectiveness of Global Vaccination Campaign: A Systematic Review of Cases Reported in Literature

Muzio, L. L., Ambosino, M., Muzio, E. L., & Quadri, M. F. A. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182011001 · Cited by 15

Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera

Hu, J., Wei, X., Jin, X., Peng, P., Xu, F.-L., Wu, K., Luo, F., Jin, A., Fang, L., Liu, B., et al. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.11.007 · Cited by 25

Comorbidities and Vaccination Status of COVID-19 All-Cause Mortality at a Tertiary Care Center of Western India

Verma, M., Sharma, S., Kumar, A., Hakim, A., Bhansali, S., & Meena, R. (2022) · Cureus · doi:10.7759/cureus.21721 · Cited by 15

Clinico-Epidemiological Profile of Breakthrough COVID-19 Infection among Vaccinated Beneficiaries from a COVID-19 Vaccination Centre in Bihar, India

Singh, C. M., Singh, P. K., Naik, B. N., Pandey, S., Nirala, S. K., & Singh, P. K. (2022) · Ethiopian Journal of Health Sciences · doi:10.4314/ejhs.v32i1.3 · Cited by 16

Humoral and Cellular Response of Transplant Recipients to a Third Dose of mRNA SARS-CoV-2 Vaccine: A Systematic Review and Meta-analysis

Bailey, A., Maganti, H., Cheng, W., Shorr, R., Buchan, C., & Allan, D. (2022) · Transplantation · doi:10.1097/tp.0000000000004386 · Cited by 12

SARS-CoV-2-specific T cell and humoral immunity in individuals with and without HIV in an African population: a prospective cohort study

Ngalamika, O., Lidenge, S. J., Mukasine, M. C., Kawimbe, M., Kamanzi, P., Ngowi, J. R., Mwaiselage, J. D., & Tso, F. Y. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.12.009 · Cited by 16

A Sports Practitioner’s Perspective on the Return to Play During the Early Months of the COVID-19 Pandemic: Lessons Learned and Next Steps

Chiampas, G., & Ibiebele, A. L. (2021) · Sports Medicine · doi:10.1007/s40279-021-01503-z · Cited by 16

The impact of COVID-19 vaccines on the Case Fatality Rate: The importance of monitoring breakthrough infections

di Lego, V., Sánchez-Romero, M., & Prskawetz, A. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.03.059 · Cited by 17

COVID‐19 vaccine breakthrough infection among fully vaccinated healthcare workers in Duhok governorate, Iraqi Kurdistan: A retrospective cohort study

Almufty, H. B., Mamani, M. M. A., Ali, A. H., & Merza, M. A. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27985 · Cited by 18

Molecular characterization of SARS-CoV-2 detected in Tokyo, Japan during five waves: Identification of the amino acid substitutions associated with transmissibility and severity

Tsuchiya, K., Yamamoto, N., Hosaka, Y., Wakita, M., Hiki, M., Matsushita, Y., Mori, H., Hori, S., Misawa, S., Miida, T., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.912061 · Cited by 15

Breakthrough Symptomatic COVID-19 Infections Leading to Long Covid: Report from Long Covid Facebook Group PollPreprint

Massey, D. S., Berrent, D., & Krumholz, H. M. (2021) · medRxiv · doi:10.1101/2021.07.23.21261030 · Cited by 18

Mounting evidence for immunizing previously infected subjects with a single dose of SARS-CoV-2 vaccine

Marc, G. P., Álvarez-Paggi, D., & Polack, F. P. (2021) · Journal of Clinical Investigation · doi:10.1172/jci150135 · Cited by 15

A longitudinal study of humoral immune responses induced by a 3-dose inactivated COVID-19 vaccine in an observational, prospective cohort

Tao, Y., Ma, M., Hu, F., Li, M., Geng, Y., Wan, Y., Mao, M., Chen, L., Shen, Y., Zhu, L., et al. (2022) · BMC Immunology · doi:10.1186/s12865-022-00532-1 · Cited by 15

Assessment of Immunogenic and Antigenic Properties of Recombinant Nucleocapsid Proteins of Five SARS-CoV-2 Variants in a Mouse Model

Rak, A. Y., Gorbunov, N., Kostevich, V. A., Av, S., Игоревна, П. П., Георгиевна, Р. Л., & Николаевна, И.-С. И. (2023) · Viruses · doi:10.3390/v15010230 · Cited by 15

Dynamically adjusted strategy in response to developments in the COVID-19 pandemic as a new normal

Shen, W. (2021) · Globalization and Health · doi:10.1186/s12992-021-00746-9 · Cited by 16

Supramolecular filaments for concurrent ACE2 docking and enzymatic activity silencing enable coronavirus capture and infection prevention

Anderson, C. F., Wang, Q., Stern, D., Leonard, E. K., Sun, B., Fergie, K. J., Choi, C.-Y., Spangler, J. B., Villano, J., Pekosz, A. S., et al. (2022) · Matter · doi:10.1016/j.matt.2022.11.027 · Cited by 14

Assembly of Immunogenic Protein Particles toward Advanced Synthetic Vaccines

Chen, S., Quan, D. H., Sam, G., Ozberk, V., Wang, X. T., Halfmann, P., Pandey, M., Good, M. F., Kawaoka, Y., Britton, W. J., et al. (2022) · Small · doi:10.1002/smll.202205819 · Cited by 15

SARS‐CoV‐2 variants and spike mutations involved in second wave of COVID‐19 pandemic in India

Muttineni, R., Binitha, R. N., Putty, K., Marapakala, K., Sandra, K. P., Panyam, J., Aravind, V., Singh, S. M., Balachandran, S., Viroji Rao, S. T., et al. (2022) · Transboundary and Emerging Diseases · doi:10.1111/tbed.14508 · Cited by 15

A novel highly potent inhibitor of TMPRSS2-like proteases blocks SARS-CoV-2 variants of concern and is broadly protective against infection and mortality in micePreprint

Shapira, T., Monreal, I. A., Dion, S. P., Jager, M. C., Désilets, A., Olmstead, A. D., Vandal, T., Buchholz, D. W., Imbiakha, B., Gao, G., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.03.442520 · Cited by 15

Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities

Liu, S., Kang, M., Zhao, N., Zhuang, Y., Li, S., & Song, T. (2022) · Medical Review · doi:10.1515/mr-2021-0021 · Cited by 15

Integrative systems immunology uncovers molecular networks of the cell cycle that stratify COVID‐19 severity

Prado, C. A. D. S., Fonseca, D. L. M., Singh, Y., Filgueiras, I. S., Baiocchi, G. C., Plaça, D. R., Marques, A. H. C., Dantas‐Komatsu, R. C. S., Usuda, J. N., Freire, P. P., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28450 · Cited by 13

A broad neutralizing nanobody against SARS-CoV-2 engineered from an approved drug

Liu, Q., Cai, C., 黄燕燕, Zhou, L., Guan, Y., Fu, S., Lin, Y., Yang, T., Yan, H., Zhang, Z., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06802-7 · Cited by 14

Mutational Landscape and Interaction of SARS-CoV-2 with Host Cellular Components

Srivastava, M., Hall, D., Omoru, O. B., Gill, H. M., Smith, S., & Janga, S. C. (2021) · Microorganisms · doi:10.3390/microorganisms9091794 · Cited by 13

Assessment of Simulated Surveillance Testing and Quarantine in a SARS-CoV-2–Vaccinated Population of Students on a University Campus

Motta, F. C., McGoff, K. A., Deckard, A., Wolfe, C. R., Bonsignori, M., Moody, M. A., Cavanaugh, K., Denny, T. N., Harer, J., & Haase, S. B. (2021) · JAMA Health Forum · doi:10.1001/jamahealthforum.2021.3035 · Cited by 14

Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers

Marra, A. R., Miraglia, J. L., Malheiros, D. T., Guozhang, Y., Teich, V., Victor, E. D. S., Pinho, J. R. R., Cypriano, A. S., Vieira, L. W., Polonio, M., et al. (2022) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2022.50 · Cited by 14

SARS-CoV-2 Vaccine Alpha and Delta Variant Breakthrough Infections Are Rare and Mild but Can Happen Relatively Early after Vaccination

Peter, J. K., Wegner, F., Gsponer, S., Helfenstein, F., Roloff, T. C., Tarnutzer, R., Grosheintz, K., Back, M., Schaubhut, C., Wagner, S., et al. (2022) · Microorganisms · doi:10.3390/microorganisms10050857 · Cited by 12

Computation of Antigenicity Predicts SARS-CoV-2 Vaccine Breakthrough Variants

Hu, Y., Hu, J., Gong, H., Danchin, A., Sun, R., Chu, H., Hung, I. F., Yuen, K., To, K. K., Zhang, B., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.861050 · Cited by 15

A Paradigm Shift in the Combination Changes of SARS-CoV-2 Variants and Increased Spread of Delta Variant (B.1.617.2) across the World

Chakraborty, C., Sharma, A. R., Bhattacharya, M., Agoramoorthy, G., & Lee, S. (2022) · Aging and Disease · doi:10.14336/ad.2021.1117 · Cited by 14

Prevalence, severity, and risk factor of breakthrough infection after vaccination with either the Covaxin or the Covishield among healthcare workers: A nationwide cross-sectional study

Krishna, B., Gupta, A., Meena, K., Gaba, A., Krishna, S., Jyoti, R., Aeron, N., Prashanth, S., Samriti, & Ganapathy, U. (2022) · Journal of Anaesthesiology Clinical Pharmacology · doi:10.4103/joacp.joacp_436_21 · Cited by 14

Genomic surveillance of SARS-CoV-2 in COVID-19 vaccinated healthcare workers in Lebanon

Alkalamouni, H., Hassan, F. F. A., Hamdan, M. B., Page, A. J., Lott, M. C., Matthews, M., Ghosn, N., Rady, A., Mahfouz, R. A., Araj, G. F., et al. (2023) · BMC Medical Genomics · doi:10.1186/s12920-023-01443-9 · Cited by 16

The End or a New Era of Development of SARS-CoV-2 Virus: Genetic Variants Responsible for Severe COVID-19 and Clinical Efficacy of the Most Commonly Used Vaccines in Clinical Practice

Miteva, D., Kitanova, M., Batselova, H., Lazova, S., Chervenkov, L., Peshevska-Sekulovska, M., Sekulovski, M., Gulinac, M., Vasilev, G., Tomov, L., et al. (2023) · Vaccines · doi:10.3390/vaccines11071181 · Cited by 16

SARS-CoV-2 vaccine breakthrough infections among healthcare workers in a large Belgian hospital network

Geysels, D., Damme, P. V., Verstrepen, W. A., Bruynseels, P., Janssens, B., Smits, P., & Naesens, R. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.326 · Cited by 13

Comparative Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Variants in the Ferret Model

Pulit-Penaloza, J. A., Belser, J. A., Sun, X., Pappas, C., Brock, N., Kieran, T. J., Ritter, J. M., Seixas, J. N., Jones, J. E., Thakur, P. B., et al. (2022) · mBio · doi:10.1128/mbio.02421-22 · Cited by 13

Exploration on wastewater-based epidemiology of SARS-CoV-2: Mimic relative quantification with endogenous biomarkers as internal reference

Tang, L., Wu, J., Liu, R., Feng, Z., Zhang, Y., Zhao, Y., Li, Y., & Yang, K. (2022) · Heliyon · doi:10.1016/j.heliyon.2023.e15705 · Cited by 14

Potential therapeutic effects and nano-based delivery systems of mesenchymal stem cells and their isolated exosomes to alleviate acute respiratory distress syndrome caused by COVID-19

Ghiasi, M., Zarandi, P. K., Dayani, A., Salimi, A., & Shokri, E. (2024) · Regenerative Therapy · doi:10.1016/j.reth.2024.03.015 · Cited by 13

The Immunopathobiology of SARS-CoV-2 Infection

Patel, M., Shahjin, F., Cohen, J. D., Hasan, M., Machhi, J., Chugh, H., Singh, S., Das, S., Kulkarni, T. A., Herskovitz, J., et al. (2021) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuab035 · Cited by 15

Therapeutic prevention of COVID-19 in elderly: a case–control study

Blanc, F., Waechter, C., Vogel, T., Schorr, B., Demuynck, C., Martin‐Hunyadi, C., Meyer, M., Mutelica, D., Bougaa, N., Fafi‐Kremer, S., et al. (2021) · GeroScience · doi:10.1007/s11357-021-00397-z · Cited by 23

An analysis of antibody responses and clinical sequalae of the Sinopharm HB02 COVID19 vaccine in dialysis patients in the United Arab Emirates

Holt, S. G., Mahmoud, S., Ahmed, W., Acuna, J. M., Madani, A. K. A., Eltantawy, I., Zaher, W. A., Goodier, G. J., Kaabi, N. A. M. A., & Obaidli, A. (2021) · Nephrology · doi:10.1111/nep.13980 · Cited by 13

Clinical Characteristics and Outcomes of COVID-19 Hospitalized Patients: A Comparison between Complete mRNA Vaccination Profile and Natural Immunity

Marincu, I., Cîtu, C., Bratosin, F., Bogdan, I. G., Timircan, M. O., Gurban, C., Bota, A. V., Brăescu, L., & Grigoraş, M. L. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020259 · Cited by 14

Determining the Reliability of Rapid SARS-CoV-2 Antigen Detection in Fully Vaccinated Individuals

Poopalasingam, N., Korenkov, M., Ashurov, A., Strobel, J., Fish, I., Hellmich, M., Gruell, H., Lehmann, C., Heger, E., & Klein, F. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105119 · Cited by 15

University population-based prospective cohort study of SARS-CoV-2 infection and immunity (SARSSURV-ULiège): a study protocol

Donneau, A., Guillaume, M., Bours, V., Dandoy, M., Darcis, G., Desmecht, D. J.-M., Diep, A. N., Fiévez, L., Garigliany, M., Gillain, N., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-055721 · Cited by 12

Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines

Pecetta, S., Kratochvil, S., Kato, Y., Vadivelu, K., & Rappuoli, R. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000285 · Cited by 11

Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model

Imbrechts, M., Maes, W., Ampofo, L., den Berghe, N. V., Calcoen, B., Looveren, D. V., Kerstens, W., Rasulova, M., Vercruysse, T., Noppen, S., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104705 · Cited by 13

Explore the attitudes of children and adolescent parents towards the vaccination of COVID-19 in China

Wang, L., Wen, W., Chen, C., Tang, J., Wang, C., Zhou, M., Cheng, Y., Zhang, X., Wang, M., Feng, Z., et al. (2022) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-022-01321-7 · Cited by 12

Variant-specific antibody response following repeated SARS-CoV-2 vaccination and infection

Jiang, X., Song, X., Shi, C., Yang, G., Wang, X., Zhang, Y.-W., Wu, J., Zhao, L., Zhang, M., Wang, M., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114387 · Cited by 13

Immunopathogenesis of Different Emerging Viral Infections: Evasion, Fatal Mechanism, and Prevention

Yang, B., & Yang, K. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690976 · Cited by 14

Clinical Outcomes of Adult Patients Hospitalized with COVID-19 after Vaccination

Kalligeros, M., Shehadeh, F., Mylona, E. K., Kaczynski, M., Kalagara, S., Atalla, E., Tsikala-Vafea, M., & Mylonakis, E. E. (2021) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed6040175 · Cited by 13

Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy

Zhou, D., Zhou, R., & Chen, Z. (2021) · Immunotherapy Advances · doi:10.1093/immadv/ltab027 · Cited by 12

Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City

Duerr, R., Dimartino, D., Marier, C., Zappile, P., Wang, G., Lighter, J., Elbel, B. D., Troxel, A. B., & Heguy, A. (2021) · Journal of Clinical Investigation · doi:10.1172/jci152702 · Cited by 53

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals

Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., Caspi, I., Levy, R., Leshchinsky, M., Ken Dror, S., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01413-7 · Cited by 373

Low‐frequency variants in mildly symptomatic vaccine breakthrough infections presents a doubled‐edged sword

Magalis, B. R., Mavian, C. N., Tagliamonte, M. S., Rich, S. N., Cash, M. N., Riva, A., Loeb, J. C., Norris, M. H., Amador, D. M., Zhang, Y., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27726 · Cited by 9

In-depth Characterization of Vaccine Breakthrough Infections With SARS-CoV-2 Among Health Care Workers in a Dutch Academic Medical Center

Rümke, L. W., Groenveld, F. C., van Os, Y. M. G., Praest, P., Tanja, A. A. N., de Jong, D. C. M., Symons, J., Schuurman, R., Reinders, T., Hofstra, L. M., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab553 · Cited by 6

Rate and risk factors for breakthrough SARS-CoV-2 infection after vaccination

Butt, A. A., Khan, T., Peng, Y., Shaikh, O. S., Omer, S. B., & Mayr, F. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.05.021 · Cited by 53